Question 1

What is an FDA Form 483?

Accepted Answer

A Form FDA 483, "Inspectional Observations," is issued by an FDA investigator at the close of an inspection when conditions are observed that, in the investigator’s judgment, may violate the Food, Drug, and Cosmetic Act or related regulations. It is a list of observations, not a final agency determination or a finding that a law was broken. The firm is expected to respond with corrective actions, which the FDA weighs alongside the inspection record when deciding the final classification or any enforcement.

Question 2

What does this database currently include?

Accepted Answer

It indexes FDA-published Form 483 records from the FDA’s Office of Inspections and Investigations (OII) FOIA Electronic Reading Room, organized by firm, FDA Establishment Identifier (FEI), establishment type, and country, with full firm-level history. Inspection classifications (OAI / VAI / NAI) and inspection citations (the CFR and FD&C Act references cited during inspections) come from the credentialed FDA Data Dashboard feed and activate automatically across the database once that feed is connected. Until then, those inspection-only sections are hidden rather than shown as empty, so the tool never implies a "clean record" from missing data.

Question 3

What is the difference between a Form 483 and an FDA Warning Letter?

Accepted Answer

A Form 483 is issued on-site at the end of an inspection and lists the investigator’s observations. A Warning Letter is a later, formal enforcement communication from the FDA, typically issued after the agency reviews the inspection, the 483 observations, and the firm’s response and concludes that significant violations remain. In short: a 483 documents observations; a Warning Letter signals that the FDA considers the issues serious enough to demand prompt correction and may escalate further.

Question 4

What do the FDA inspection classifications OAI, VAI, and NAI mean?

Accepted Answer

After an inspection, the FDA assigns a final classification: NAI (No Action Indicated) means no objectionable conditions were found; VAI (Voluntary Action Indicated) means objectionable conditions were found but the FDA expects the firm to correct them voluntarily; and OAI (Official Action Indicated) means significant objectionable conditions were found and regulatory or administrative action is warranted. OAI is the most serious of the three and is the classification most associated with follow-on Warning Letters, import alerts, or other enforcement.

Question 5

What is an FEI number?

Accepted Answer

An FEI (FDA Establishment Identifier) is the unique number the FDA assigns to a facility it regulates. Because the same site can appear under several legal or trade names over time, this database uses the FEI as the canonical key — rolling up Form 483 records (and, when connected, inspections and citations) for a facility under one firm profile and listing the alternate names it has been recorded under.

Question 6

How current is the data and where does it come from?

Accepted Answer

The FDA refreshes its published inspectional and compliance data weekly, and that data reflects final actions only. Form 483 records are sourced from the OII FOIA Electronic Reading Room; inspection classifications and citations are sourced from the FDA Data Dashboard. Every record keeps source provenance with the URL it was fetched from, and the "Synced" indicator in the page header shows the last successful sync.

Question 7

Why might a specific inspection or firm not appear?

Accepted Answer

FDA-published data covers final actions and is not a comprehensive listing of every FDA inspection. State-contract inspections, pre-approval inspections, and pending or in-progress actions may not be reflected. Because inspected project areas are counted separately, project-area classifications can also exceed the number of distinct inspections. A published 483 can appear in the FOIA reading room even when a matching inspection is not yet shown in the FDA Data Dashboard.

Question 8

What does a CFR citation like "21 CFR 211" refer to?

Accepted Answer

Inspection citations reference the section of the Code of Federal Regulations (CFR) an observation relates to. In FDA practice, 21 CFR 210–211 cover current Good Manufacturing Practice (cGMP) for finished pharmaceuticals, 21 CFR 820 is the Quality System Regulation for medical devices, 21 CFR 606 covers blood and blood components, and 21 CFR 111 covers dietary supplements. Citations may also reference sections of the FD&C Act itself. This lets regulatory and quality teams see exactly which requirements an observation maps to.

Question 9

How can I use a firm’s Form 483 history to assess inspection risk?

Accepted Answer

Look at how frequently and how recently a firm has received Form 483s, the establishment type and products involved, and whether observation themes repeat across inspections — recurring or recent findings are a stronger signal than a single old one. A firm’s 483 history is a useful supplier-due-diligence and benchmarking input, but it is not a verdict: it does not capture the firm’s corrective actions, its responses, or the FDA’s final classification. Treat it as one evidence-based input alongside the firm’s own quality and CAPA record.

Question 10

Is this official FDA data, and is Assyro affiliated with the FDA?

Accepted Answer

The records here are sourced from public FDA datasets, and every record links back to its FDA source. Assyro is an independent regulatory-compliance platform and is not affiliated with, endorsed by, or acting on behalf of the FDA. For official determinations, always consult the FDA’s own systems and the firm’s official correspondence.

FDA Inspection Database

Top establishment types

Foreign vs domestic

Form 483 activity

Top countries

Record types

Controlled vocabulary and relationship rules

Get alerted the moment your firm — or a competitor — gets a 483.

FDA inspection & Form 483 FAQ